Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients - Related Studies

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

This study has been completed.

Study NCT00034255. Last updated on June 23, 2005. Information provided by GMP Endotherapeutics

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Diabetes Mellitus, Type 1
		Diabetes Mellitus, Type 2

2	Additional conditions recognized in this trial
		Diabetes Mellitus

3	More general conditions related to this trial
		Autoimmune Diseases
		Endocrine System Diseases
		Glucose Metabolism Disorders
		Immune System Diseases
		Metabolic Diseases

4	Interventions listed in this trial
		INGAP Peptide

5	Sponsors listed in this trial
		GMP Endotherapeutics